AKBA Stock Recent News

AKBA LATEST HEADLINES

AKBA Stock News Image - Reuters

The U.S. Food and Drug Administration approved Akebia Therapeutics' drug to treat anemia caused by chronic kidney disease in dialysis patients, the drugmaker said on Wednesday.

Reuters 2024 Mar 27
AKBA Stock News Image - Zacks Investment Research

Akebia Therapeutics (AKBA) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.04 per share a year ago.

Zacks Investment Research 2024 Mar 14
AKBA Stock News Image - PRNewsWire

CAMBRIDGE, Mass. , March 11, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to report fourth quarter and full year 2023 financial results on March 14, 2024.

PRNewsWire 2024 Mar 11
AKBA Stock News Image - PRNewsWire

CAMBRIDGE, Mass. , Nov. 20, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Tuesday, November 28 th at 10:30 a.m.

PRNewsWire 2023 Nov 20
AKBA Stock News Image - Zacks Investment Research

Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research 2023 Oct 26
AKBA Stock News Image - PennyStocks

If you're looking to gain an edge in the stock market today, you've got to have more than a list of penny stocks to watch. You need to understand how to use the wild volatility that has been created this year to your advantage.

PennyStocks 2023 Aug 28
AKBA Stock News Image - Zacks Investment Research

Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to earnings of $0.23 per share a year ago.

Zacks Investment Research 2023 Aug 25
AKBA Stock News Image - PRNewsWire

Akebia to Host Conference Call on August 25 th at 9:00 a.m. ET CAMBRIDGE, Mass.

PRNewsWire 2023 Aug 23
AKBA Stock News Image - PRNewsWire

CAMBRIDGE, Mass. , July 19, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will participate in a fireside chat at the H.C.

PRNewsWire 2023 Jul 19
AKBA Stock News Image - PennyStocks

There are so many new traders and investors entering the stock market today. But if you're brand new, you might not have a lot of money to invest or don't want to risk a whole lot while you're learning how to trade.

PennyStocks 2023 Jul 10
10 of 50